Zynex reports Q3 EPS 10c, consensus 9c

Reports Q3 revenue $49.9M, consensus $49.87M. “Q3 was highlighted by increasing revenue and cash flow momentum driven by our sixth straight quarter of record-high order numbers,” said CEO Thomas Sandgaard. “As we continue to develop the next generation of patient monitoring equipment, our pain management division delivered a 39% improvement in orders year-over-year and celebrated our 1 millionth patient treated since founding the company. Our continued profitability and record positive cash flow allowed us to announce an additional $10 million share repurchase plan…We continue to focus on profitable growth by adding products to our suite in complementary ways that combine with our industry-leading prescription strength pain management device, the NexWave….We continue to expand our direct salesforce and continue to improve sales rep productivity which delivers accelerating and recurring revenue. In tandem we focused on ramping our hospital monitoring division which represents a large and growing market opportunity. We look forward to additional updates in the months to come as we work to build long term value for our shareholders”.